Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | CTSV | O60911 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18580669 | 0.87 | ALDH1A1 (0.38) | SMN1; SMN2NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL2849688 | 0.87 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9ACTSLCTSB | |
| SCHEMBL18580589 | 0.87 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9ACYP2C19S1PR5 | |
| SCHEMBL2849683 | 0.87 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9ACTSLCTSB | |
| SCHEMBL18579802 | 0.86 | AXL (0.39) | SMN1; SMN2S1PR5KDM1A | |
| SCHEMBL8134699 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9ACTSLCTSB | |
| SCHEMBL27484279 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9ACTSLCTSB | |
| SCHEMBL27160337 | 0.84 | TEAD1 (0.48) | MAOBKMT2A | |
| SCHEMBL18040923 | 0.84 | BCHE (0.43) | SMN1; SMN2NPC1RAB9ACTSLCTSB | |
| SCHEMBL31669166 | 0.83 | BACE1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-3523292-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-15 | — | — | EP | disclosed |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-02 | — | — | US | disclosed |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-03-16 | — | — | US | disclosed |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-02-09 | — | — | US | disclosed |
| EP-3344613-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A ST CO., LTD. (KR) | 2019-10-17 | — | — | US | disclosed |
| EP-3523292-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | Dong-A Socio Holdings Co., Ltd. (KR) | 2019-08-14 | — | — | EP | disclosed |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2019-04-25 | — | — | US | disclosed |
| US-10125118-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2018-11-13 | — | — | US | disclosed |
| EP-3344613-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | Dong-A Socio Holdings Co., Ltd. (KR) | 2018-07-11 | — | — | EP | disclosed |
| WO-2018071343-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2018-04-19 | — | — | WO | disclosed |
| US-20170355690-A9 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-12-14 | — | — | US | disclosed |
| US-20170066742-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO LTD (KR) | 2017-03-09 | — | — | US | disclosed |
| WO-2017039331-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355690-A9 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | SMN1; SMN2 3426/4885NPC1 1134/4885RAB9A 1486/4885 |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB4 | SMN1; SMN2 2038/4885NPC1 940/4885RAB9A 1197/4885 |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | SMN1; SMN2 3426/4885NPC1 1134/4885RAB9A 1486/4885 |
| US-10125118-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | SMN1; SMN2 3426/4885NPC1 1134/4885RAB9A 1486/4885 |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB4 | SMN1; SMN2 2038/4885NPC1 940/4885RAB9A 1197/4885 |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB2 | SMN1; SMN2 2563/4885NPC1 649/4885RAB9A 1364/4885 |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | SMN1; SMN2 3426/4885NPC1 1134/4885RAB9A 1486/4885 |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | SMN1; SMN2 3426/4885NPC1 1134/4885RAB9A 1486/4885 |
| US-20170066742-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | SMN1; SMN2 3426/4885NPC1 1134/4885RAB9A 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.